Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility

Published on: 
In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter, August 2021, Volume 16, Issue 08

The GMP facility is designed to maximize bioprocessing efficiency of newborn stem cells and manufacturing at scale.

Generate Life Sciences announced the establishment of its good manufacturing practice (GMP) facility in La Jolla, Calif. for newborn stem cell biologics end-to-end manufacturing. This facility will add the role of a personalized therapeutics developer with in-house manufacturing capabilities to the company’s core international donor gamete, genetics service, and newborn stem cell preservation business.

With its bioreactor system, automation, and its meeting cGMP regulations, the new facility is designed to maximize bioprocessing efficiency of newborn stem cells and manufacturing at scale.

"The La Jolla GMP facility will be a crucial addition to Generate's vision for our newborn stem cell operation," said Jaime Shamonki, chief medical officer of Generate Life Sciences, in a press release. "As the largest private newborn stem cell biorepository in the world, we believe it is our duty to continually invest in new scientific applications for newborn stem cells with the goal to increase access to novel therapies for families. With this facility, we will have the in-house capability to take these stem cells through the complete process of collection, cryogenic storage, and ultimately biologics manufacturing. This will allow us to power our studies in a much more efficient and streamlined manner and help us better serve the families who have stored over 1.2 million stem cell units with us."


Mesenchymal stem cells (MSCs) can be isolated from the umbilical cord tissue and used in regenerative medicine due to their anti-inflammatory, immune-modulating, and tissue reparative properties. Researchers and scientists are targeting the use of MSCs for the treatment of conditions such as autoimmune disease, acquired neurological diseases, lung disease, and conditions related to infertility. In addition, MSCs are being used in clinical trials for cell therapy, gene therapy, tissue-engineering, and combination products.

Source: Generate Life Sciences